Abstract: Clin Microbiol Infect ABSTRACT: The aim of this study was to investigate travel-associated morbidity in European travellers in 2009 in comparison with 2008, with a particular emphasis on emerging infectious diseases with the potential for introduction into Europe. Diagnoses with demographic, clinical and travel-related predictors of disease from ill returning travelers presenting to 12 core EuroTravNet sites from January to December 2009 were analysed. A total of 6392 patients were seen at EuroTravNet core sites in 2009, as compared with 6957 in 2008. As compared with 2008, there was a marked increase in the number of travellers exposed in North America and western Europe. Respiratory illnesses, in particular pandemic A(H1N1) influenza, influenza-like syndromes, and tuberculosis, were also observed more frequently. A significant increase in reported dengue cases in 2009 as compared with 2008 was observed (n = 172, 2.7% vs. n = 131, 1.90%) (p 0.002). The numbers of malaria and chikungunya cases were also increasing, although not significantly. Two deaths were recorded: visceral leishmaniasis and sepsis in a Sudanese migrant, and Acinetobacter sp. pneumonia in a patient who had visited Spain. This is the most comprehensive study of travel-related illness in Europe in 2009 as compared with 2008. A significant increase in travel-related respiratory and vector-borne infections was observed, highlighting the potential risk for introduction of these diseases into Europe, where competent vectors are present. The number of traveller deaths is probably underestimated. The possible role of the travellers in the emergence of infectious diseases of public health concern is highlighted. tious diseases of public health concern is highlighted.
Introduction
The international circulation of microorganisms, vectors and infected individuals and animals poses a global public health threat, and requires attention at the national and international levels. In 2009, 12 EuroTravNet sites from nine European countries, also belonging to the global GeoSentinel surveillance system (http://www.eurotravnet.eu ), contributed to this study, whose aim was to describe demographic, epidemiological and clinical characteristics of ill travellers who presented in 2009 in order to assess the importance of infectious diseases that are non-endemic in Europe, but have the potential for re-introduction. Comparison with 2008 data [1] was performed when appropriate.
Patients and Methods
We included patients who presented from 1 January to 31 December 2009 at any of the participating EuroTravNet sites with a history of international travel and a travel-associated complaint as judged by the treating physician, as described previously [2] . Some patients were found to have no morbidity after examination. Reasons for travel were grouped into eight main categories (Table 1) . Specific diagnoses from a list of 688 items were grouped into 22 broad syndromes, and countries of likely exposures were grouped into 13 regions (Table 1 ) [1] . Data were analysed with SPSS v16.0 (SPSS, Chicago, IL, USA). Owing to the absence of a true denominator, no incidence rates or risk estimates can be calculated. Rather, proportionate morbidity was used, comparing the number of cases of a specific diagnoses or syndrome with all cases of ill returned travellers seen during the same time period. Differences in proportionate morbidity between 2009 and 2008 in ill returned travellers seen at EuroTravNet core sites were tested with Pearson chi-square or Fisher exact tests. t-Tests were used for continuous variables. A p-value of <0.01 was chosen to adjust for the large number of statistical tests performed.
Results
The same core sites contributed patients to the analysis in 2008 and 2009, although the proportionate contribution varied over time in some of the sites (Table 2) .
Demographics and patient characteristics
In 2009, 6392 patients with travel-associated health complaints were seen at the participating institutions (n = 6957 in 2008). Information about demographics, reason for travel, risk level and clinical setting is given in Table 1 . (20 adults and six children overall). Adult patients were European travellers (n = 12) or expatriates (n = 4) and migrants (n = 4). Six cases occurred in children: two immigrants and four children born in Europe who were visiting friends and relatives (VFR). They were mainly exposed in West Africa (Burkina Faso, Ghana, Guinea (two cases), and Nigeria) and Malawi.
Dengue: Dengue was the second most frequent cause of fever among ill returning travellers, with 172/6392 cases (Fig. 1) . Influenza-like illnesses that were not confirmed as pandemic A(H1N1) influenza were seen in patients exposed in the USA, Spain, and the UK, although there were also cases from Thailand and India.
Chagas disease: The number of reported new Chagas cases, detected by serology, decreased from 94/6957 (1.4%) to 30/6392 (0.5%) (p £0.001).
Chronic diseases. There was a significant increase in the proportion of reported tuberculosis (TB) cases, from 1.5% in 2008 to 2.1% in 2009 (p 0.003), primarily from the clinic in Brescia. Human immunodeficiency virus (HIV)/AIDS represented the most frequent chronic diagnosis, followed by active TB and latent TB. Of the HIV/AIDS cases, 217 were migrants, and 76 were non-migrants. Arriving immigrants accounted for 163 cases, and the remaining cases were mainly VFR travellers. 
Discussion
Travel-related illnesses may have important public health consequences if conditions for re-introduction of diseases are met [3] . In our dataset, in 2008 and 2009, five deaths were reported. This is probably an underestimate of the mortality burden, as it does not include patients who died overseas, and patients who die may be more likely to be seen in other types of clinic.
During the last few years, the number of imported malaria cases in Europe has decreased, possibly reflecting malaria control activities in endemic countries [4, 5] . However, malaria in Europe remains an important travel medicine issue, given the large number of imported cases [6] . Moreover, there is potential for the reappearance of malaria in countries where it was previously eradicated, and limited outbreaks do occur in Europe, where Anopheles mosquitoes are still present, mainly in the Mediterranean area [7] , making the slight, although not statistically significant, increase observed in our dataset in 2009 a phenomenon that requires attention. In August 2006, one case of indigenous P. vivax malaria was diagnosed in Corsica [8] , and in October 2010, another was diagnosed in Aragon, Spain, where the vector, Anopheles atroparvus, is present [9] .
Dengue is the second most common cause of fever in returned ill travellers [10] . The increase in the number of dengue cases observed in 2009 is mainly attributable to the increased participation of the clinic in Amsterdam, with patients coming from the Netherlands Antilles and Suriname, and to an increase in the numbers of patients coming from Thailand and Vietnam, where dengue outbreaks in 2009 were reported [11, 12] . In Mediterranean countries, the presence of Aedes albopictus can facilitate autochthonous cases [3] . In August 2010, a case of dengue fever acquired in southern Croatia in a traveller from Germany was reported [13] , and in September 2010 two cases of autochthonous dengue fever were diagnosed in metropolitan France (Nice) for the first time. This strongly suggests that local transmission of dengue is ongoing [14] . Increased surveillance for dengue with mosquito control and increased vigilance by health professionals is needed [15] .
Chikungunya remains an important global public health problem, with several outbreaks occurring worldwide, such as in Malaysia and Thailand in 2009. Chikungunya activity is ongoing in the French island of Reunion [16] . Since the 1980s, A. albopictus has spread worldwide, including to southern Europe [17] . After the Italian outbreak in 2007 [3] , two autochthonous cases of chikungunya fever were reported in France, in September 2010 [18] . Climate changes, urbanization and international transport may facilitate the enlargement of areas endemic for chikungunya and other vectortransmitted infections, posing a threat to global public health even in areas previously considered to be safe, such as Europe. The presence of adequate vectors in Europe may favour the stable introduction of vector-borne diseases [19] .
Chagas disease is a potentially life-threatening illness, affecting over 10 million people, originating mainly from Latin America. Although the vector (Triatominae spp.) is not present on the European continent, the chronic nature of the disease, together with the migration flow from endemic countries, can have a public health impact in Europe [20] , as it is potentially transmissible to the autochthonous population through contaminated blood products, and also causes congenital and chronic diseases [21] . Owing to its historical links with Latin America, Spain reports the highest number of Chagas cases in Europe. A moderate decrease in the number of cases of Chagas infection detected by serology was observed in 2009. This is probably attributable to the 2009 economic crisis, which has forced many migrants to return to their country origin, or to a cohort effect, after much of the Bolivian migrant community in Madrid was screened in 2008. Efforts are needed to improve knowledge of Chagas disease among physicians [22] and to develop screening and control in blood banks, organ donation, and at-risk pregnant women.
Pandemic A(H1N1) influenza was first detected in the USA on 15 April 2009, and the WHO declared it a Public Health Emergency of International Concern on 25 April 2009. Recommendations to countries to intensify surveillance were soon issued [23] . In our dataset, after the first case, reported on 28 April in a European traveller returning from Mexico, the number of confirmed reported cases peaked in July 2009. Pandemic A(H1N1) influenza cases were primarily diagnosed, in decreasing order, in students and tourists exposed in the USA, the UK, Spain, Argentina, and Mexico. As pandemic A(H1N1) influenza became a global problem, we observed a progressive decrease in the number of cases reported in Europe, potentially reflecting the widespread management of these patients at various levels of the European health systems, as well as the possibility that new cases of pandemic A(H1N1) influenza were now more likely to be acquired locally rather than through travel. Our data underline the usefulness of surveillance networks to monitor an unexpected epidemic event in Europe. Pandemic A(H1N1) influenza greatly affected the profile of the patients observed in our network, with a shift to travellers and students returning from North America [24] .
The small increase in the number of TB cases may reflect the changing composition of newly arriving migrant communities, particularly Pakistani and Indian migrants, in Brescia, Italy, a popular destination for migrants in Italy. The impact of imported TB on the local epidemiology may vary from country to country [25] . These numbers may change from year to year as migration patterns change, and could therefore be a marker for the possibility of other illnesses in migrants.
Most of the cases of HIV/AIDS in our study were in immigrants. The long incubation periods of HIV/AIDS and TB make it very difficult to ascribe these infections to a specific travel episode or to an infectious condition existing before travel in migrants [26, 27] . Pre-travel and post-travel advice by infectious disease specialists will be important, as the prevalence of HIV infection is expected to rise as AIDSrelated mortality is decreasing [28] .
We recognize the following limitations that may possibly make time comparisons less accurate. (i) The relative contributions of participating centres varied from 2008 to 2009. This means that the 2009 proportionate morbidity presents a more legitimate baseline than counts. (ii) As EuroTravNet represents a sample of travellers who sought medical care, the incidence and risk of returning with any given diagnosis cannot be calculated. However, proportionate morbidity can be calculated to compare relative frequencies of illness in ill returned travellers. (iii) Our analysis could not capture all febrile illness in travellers, because infections that have short incubation periods may manifest during travel. The patient intake at each site reflects local or national differences in the composition of the travelling population, the distribution of the travel destinations, and access to medical care. However, we are confident that the large sample size, the European heterogeneous mix of sites and patients and the quality and consistency of the collected data compensated for biases and provide useful information.
Conclusions
The timely and accurate reporting of ad hoc surveillance networks such as EuroTravNet will supplement and reinforce regular routine disease reporting, and serve as a sentinel for emerging infectious diseases. Travellers played an important role in the spread of pandemic A(H1N1) influenza, as has already occurred in the past for other airborne infections (i.e. SARS). Vector-borne infections, such as malaria, chikungunya and dengue, need ongoing surveillance as global warming, urbanization and international transport may facilitate the enlargement of endemic areas. Secondary cases may be expected, and have already been reported in Europe. Increased surveillance for mosquito control and increased vigilance by health professionals are needed.
